Tofacitinib in Rheumatoid Arthritis: Saudi Real-world Data
Annals of Rheumatology and Autoimmunity · 2023
DOI: 10.4103/ara.ara_11_23 ↗Abstract
Abstract Objectives: Tofacitinib is a potent, small molecule, orally administered, selective Janus kinase inhibitor approved for use in rheumatoid arthritis (RA). Although safety and efficacy have been proven in clinical trials, the safety information in a real-world setting from the Kingdom of Saudi Arabia (KSA) is limited. Materials and Methods: This was a retrospective real-world evidence study conducted at a single tertiary care referral center in Riyadh, KSA. Records of all adult patients aged 18–80 diagnosed with RA between 2016 and 2022 and on tofacitinib were included in this study. Results: Records of 100 patients were analyzed. The mean duration of tofacitinib use was 17.59 months. A total of 34% had discontinued tofacitinib for reasons such as active RA (35.29%) and at patients’ request (20.59%). There were no adverse events except for one patient who had a stroke. There was no statistically significant difference regarding laboratory parameters such as blood counts, liver function tests, and inflammatory markers. Conclusion: Tofacitinib was shown to have a consistent safety profile with a low incidence of adverse events up to 24 months in patients diagnosed with RA from KSA.
EUVIMED